Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Study ID
NCT00964171

Study type
Interventional

Study phase
Phase 2

Study status
Unknown status

Trial Acronym

Trial Summary

RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well efavirenz works as second-line therapy in treating patients with metastatic pancreatic cancer.

More informations

Trial Starting Date

Aug 31,2008

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

In order to facilitate the use of our website, we use cookies.